Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929596 | 0.87 | ATR (0.56) | ATRNPSR1KDM4EALDH1A1USP2 | |
| SCHEMBL1930082 | 0.86 | L3MBTL1 (0.49) | ATRNPSR1KDM4EALDH1A1USP2 | |
| SCHEMBL1930500 | 0.86 | KDM4E (0.48) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1929218 | 0.85 | NPSR1 (0.46) | ATRNPSR1KDM4EALDH1A1USP2 | |
| SCHEMBL1930354 | 0.77 | L3MBTL1 (0.50) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1929325 | 0.76 | NPC1 (0.64) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1930503 | 0.76 | L3MBTL1 (0.55) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1930408 | 0.75 | L3MBTL1 (0.46) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1930084 | 0.75 | L3MBTL1 (0.67) | NPSR1KDM4EALDH1A1USP2TSHR | |
| SCHEMBL1931087 | 0.73 | L3MBTL1 (0.46) | NPSR1KDM4EALDH1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | claimed |
| US-7956074-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | claimed |
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-08-06 | — | — | US | claimed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-7956074-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-08-06 | — | — | US | disclosed |
| US-7541372-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1968972-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | GABRA5, GABRA4, GABRA3 | ATR 3382/4885NPSR1 190/4885KDM4E 1328/4885 |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | GABRA5, GABRA4, GABRA3 | ATR 3382/4885NPSR1 190/4885KDM4E 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.